191 related articles for article (PubMed ID: 37528657)
1. Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents.
Liang S; Geng Y; Niu MM; Zhang Y; He W; Li J; Yang L; Xu Z
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241118. PubMed ID: 37528657
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel and potent dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation.
Qiao X; Wu X; Chen S; Niu MM; Hua H; Zhang Y
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2295241. PubMed ID: 38134358
[TBL] [Abstract][Full Text] [Related]
3. Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and
Jin X; Wang Y; Chen J; Niu M; Yang Y; Zhang Q; Bao G
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2289355. PubMed ID: 38059332
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1.
Ran T; Li W; Peng B; Xie B; Lu T; Lu S; Liu W
J Chem Inf Model; 2019 Jan; 59(1):522-534. PubMed ID: 30607947
[TBL] [Abstract][Full Text] [Related]
8. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
9. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
10. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Jang YG; Hwang KA; Choi KC
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
[TBL] [Abstract][Full Text] [Related]
11. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
14. Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases.
Li X; Zhang L; Xu J; Liu C; Zhang X; Abdelmoneim AA; Zhang Q; Ke J; Zhang Y; Wang L; Yang F; Luo C; Jin J; Ye F
J Chem Inf Model; 2022 Feb; 62(3):692-702. PubMed ID: 35098713
[TBL] [Abstract][Full Text] [Related]
15. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.
Majumder S; Liu Y; Ford OH; Mohler JL; Whang YE
Prostate; 2006 Sep; 66(12):1292-301. PubMed ID: 16705743
[TBL] [Abstract][Full Text] [Related]
16. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression.
Grypari IM; Logotheti S; Zolota V; Troncoso P; Efstathiou E; Bravou V; Melachrinou M; Logothetis C; Tzelepi V
Medicine (Baltimore); 2021 Sep; 100(36):e27094. PubMed ID: 34516499
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.
Kavianpour P; Gemmell MCM; Kahlert JU; Rendina LM
Chembiochem; 2020 Oct; 21(19):2786-2791. PubMed ID: 32367603
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the complexity of histone-arginine methyltransferase CARM1 in cancer: From underlying mechanisms to targeted therapeutics.
Jin W; Zhang J; Chen X; Yin S; Yu H; Gao F; Yao D
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188916. PubMed ID: 37196782
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]